Eryaspase in combination with chemotherapy (gemcitabine) was associated with improvements in overall survival (OS) and progression-free survival (PFS), irrespective of asparagine synthetase (ASNS) expression in second-line advanced pancreatic adenocarcinoma. Here, ASNS is linked to pancreatic adenocarcinoma.